US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US20040226056A1
(en)
*
|
1998-12-22 |
2004-11-11 |
Myriad Genetics, Incorporated |
Compositions and methods for treating neurological disorders and diseases
|
BR0007532A
(pt)
|
1999-01-13 |
2001-11-20 |
Univ New York State Res Found |
Métodos para identificar inibidores de proteìnaquinase, para testar compostos para umacapacidade de inibir a atividade de proteìnaquinase e para inibir uma proteìna quinase, inibidorde proteìna tirosina quinase não peptìdica, e,método de tratar uma condição responsiva a uminibidor de proteìna quinase em um paciente
|
AU2001239770B2
(en)
|
2000-02-15 |
2006-01-05 |
Pharmacia & Upjohn Company |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
MY128450A
(en)
|
2000-05-24 |
2007-02-28 |
Upjohn Co |
1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
EP1294688A2
(en)
|
2000-06-02 |
2003-03-26 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
US6635640B2
(en)
|
2000-06-30 |
2003-10-21 |
Sugen, Inc. |
4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
|
DE60126997T2
(de)
|
2000-10-20 |
2007-10-25 |
Eisai R&D Management Co., Ltd. |
Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
|
US6677368B2
(en)
*
|
2000-12-20 |
2004-01-13 |
Sugen, Inc. |
4-aryl substituted indolinones
|
AR042586A1
(es)
*
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
US7186745B2
(en)
|
2001-03-06 |
2007-03-06 |
Astrazeneca Ab |
Indolone derivatives having vascular damaging activity
|
EP1247809A3
(en)
*
|
2001-03-30 |
2003-12-17 |
Pfizer Products Inc. |
Triazine compounds useful as sorbitol dehydrogenase inhibitors
|
AR036042A1
(es)
|
2001-05-30 |
2004-08-04 |
Sugen Inc |
Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
|
US20050176687A1
(en)
*
|
2001-06-29 |
2005-08-11 |
Alain Moussy |
Use of tyrosine kinase inhibitors for treating autoimmune diseases
|
AR038957A1
(es)
*
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
JP4159988B2
(ja)
*
|
2001-08-15 |
2008-10-01 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
N−[2−(ジエチルアミノ)エチル]−5−[(5−フルオロ−1,2−ジヒドロ−2−オキソ−3h−インドール−3−イリデン)メチル]−2,4−ジメチル−1h−ピロール−3−カルボキシアミドのリンゴ酸塩を含む結晶、その製法およびその組成物
|
US6777417B2
(en)
|
2001-09-10 |
2004-08-17 |
Sugen, Inc. |
3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors
|
WO2003031438A1
(en)
*
|
2001-10-10 |
2003-04-17 |
Sugen, Inc. |
3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
|
US7005445B2
(en)
|
2001-10-22 |
2006-02-28 |
The Research Foundation Of State University Of New York |
Protein kinase and phosphatase inhibitors and methods for designing them
|
WO2003035621A1
(en)
*
|
2001-10-22 |
2003-05-01 |
The Research Foundation Of State University Of New York |
Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
|
TWI259081B
(en)
*
|
2001-10-26 |
2006-08-01 |
Sugen Inc |
Treatment of acute myeloid leukemia with indolinone compounds
|
US20030080191A1
(en)
*
|
2001-10-26 |
2003-05-01 |
Allen Lubow |
Method and apparatus for applying bar code information to products during production
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
US20050131733A1
(en)
*
|
2001-12-17 |
2005-06-16 |
Allen Lubow |
Sealable individual bar coded packets
|
WO2003052681A1
(en)
*
|
2001-12-17 |
2003-06-26 |
International Barcode Corporation |
Double-sided bar code doubling as a single bar code
|
KR100965519B1
(ko)
*
|
2001-12-27 |
2010-06-23 |
세라밴스 인코포레이티드 |
단백질 키나제 억제제로서 유용한 인돌리논 유도체
|
MXPA04006992A
(es)
*
|
2002-02-15 |
2004-11-10 |
Upjohn Co |
Procedimiento para preparar derivados de indolinona.
|
WO2003097854A2
(en)
*
|
2002-05-17 |
2003-11-27 |
Sugen, Inc. |
Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
|
ITMI20021620A1
(it)
*
|
2002-07-23 |
2004-01-23 |
Novuspharma Spa |
Composto ad ativita' antitumorale
|
WO2004016211A2
(en)
*
|
2002-08-08 |
2004-02-26 |
Vanderbilt University |
Pi3k antagonists as radiosensitizers
|
US7195876B2
(en)
*
|
2002-08-09 |
2007-03-27 |
Theravance, Inc. |
Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
|
US20040121407A1
(en)
*
|
2002-09-06 |
2004-06-24 |
Elixir Pharmaceuticals, Inc. |
Regulation of the growth hormone/IGF-1 axis
|
HN2003000272A
(es)
*
|
2002-09-10 |
2008-07-29 |
Pharmacia Italia Spa |
Formulaciones que comprenden un compuesto de indolinona
|
US7626031B2
(en)
*
|
2002-11-15 |
2009-12-01 |
Symphony Evolution, Inc. |
Substituted 3-(diarylmethylene)indolin-2-ones and methods of their use
|
AR042042A1
(es)
*
|
2002-11-15 |
2005-06-08 |
Sugen Inc |
Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
|
US7452913B2
(en)
*
|
2003-02-24 |
2008-11-18 |
Pharmacia & Upjohn Company |
Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
|
US20040209937A1
(en)
*
|
2003-02-24 |
2004-10-21 |
Sugen, Inc. |
Treatment of excessive osteolysis with indolinone compounds
|
EP2476667B1
(en)
|
2003-02-26 |
2014-07-16 |
Sugen, Inc. |
Aminoheteroaryl compounds as protein kinase inhibitors
|
US20040266843A1
(en)
*
|
2003-03-07 |
2004-12-30 |
Sugen, Inc. |
Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
|
US7157577B2
(en)
*
|
2003-03-07 |
2007-01-02 |
Sugen Inc. |
5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
|
WO2004080462A1
(ja)
*
|
2003-03-10 |
2004-09-23 |
Eisai Co., Ltd. |
c-Kitキナーゼ阻害剤
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
DE10334582A1
(de)
*
|
2003-07-28 |
2005-02-24 |
Basf Ag |
Verfahren zur Herstellung von Maleinsäureanhydrid
|
WO2005023765A1
(en)
*
|
2003-09-11 |
2005-03-17 |
Pharmacia & Upjohn Company Llc |
Method for catalyzing amidation reactions by the presence of co2
|
SI1670785T1
(sl)
*
|
2003-10-02 |
2010-10-29 |
Pharmacia & Upjohn Co Llc |
Soli in polimorfi spojine indolinona, substituirani s pirolom
|
SI1680140T1
(sl)
*
|
2003-10-16 |
2011-08-31 |
Imclone Llc |
Inhibitorji receptorja-1 za fibroblastni rastni faktor in metode za zdravljenje z le-temi
|
KR20060111520A
(ko)
|
2003-11-07 |
2006-10-27 |
카이론 코포레이션 |
Fgfr3의 억제 및 다발성 골수종의 치료
|
CN100450998C
(zh)
|
2003-11-11 |
2009-01-14 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
WO2005053686A1
(en)
*
|
2003-11-26 |
2005-06-16 |
The Scripps Research Institute |
Indolinone based protein kinase inhibitors
|
WO2005058341A2
(en)
*
|
2003-12-11 |
2005-06-30 |
Theravance, Inc. |
Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
US20050152943A1
(en)
*
|
2003-12-23 |
2005-07-14 |
Medtronic Vascular, Inc. |
Medical devices to treat or inhibit restenosis
|
WO2005118543A1
(ja)
*
|
2004-06-03 |
2005-12-15 |
Ono Pharmaceutical Co., Ltd. |
キナーゼ阻害薬およびその用途
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
SE0401790D0
(sv)
*
|
2004-07-07 |
2004-07-07 |
Forskarpatent I Syd Ab |
Tamoxifen response in pre- and postmenopausal breast cancer patients
|
US20060009510A1
(en)
*
|
2004-07-09 |
2006-01-12 |
Pharmacia & Upjohn Company Llc |
Method of synthesizing indolinone compounds
|
DK1786785T3
(da)
*
|
2004-08-26 |
2010-05-31 |
Pfizer |
Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere
|
EP1797881B1
(en)
|
2004-09-17 |
2009-04-15 |
Eisai R&D Management Co., Ltd. |
Medicinal composition with improved stability and reduced gelation properties
|
CN100432071C
(zh)
*
|
2004-11-05 |
2008-11-12 |
中国科学院上海药物研究所 |
取代1h-吲哚-2-酮类化合物及其制备方法和用途
|
GT200500321A
(es)
*
|
2004-11-09 |
2006-09-04 |
|
Compuestos y composiciones como inhibidores de proteina kinase.
|
NZ561138A
(en)
*
|
2005-03-23 |
2009-06-26 |
Pfizer Prod Inc |
Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer
|
EP1877444A2
(en)
|
2005-04-26 |
2008-01-16 |
Pfizer, Inc. |
P-cadherin antibodies
|
WO2006120557A1
(en)
*
|
2005-05-12 |
2006-11-16 |
Pfizer Inc. |
Anticancer combination therapy using sunitinib malate
|
EP2364973B1
(en)
|
2005-05-18 |
2014-07-09 |
Array Biopharma, Inc. |
Heterocyclic inhibitors of mek and methods of use thereof
|
RU2425041C2
(ru)
|
2005-05-23 |
2011-07-27 |
Новартис Аг |
Кристаллические и другие формы солей, образованных из молочной кислоты и 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она
|
MX2007014810A
(es)
*
|
2005-05-26 |
2008-02-21 |
Scripps Research Inst |
Inhibidores de la proteina quinasa mejoradas a base de indolinona.
|
EP1925941B1
(en)
|
2005-08-01 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
WO2007015578A1
(ja)
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を検定する方法
|
ES2546069T3
(es)
|
2005-09-07 |
2015-09-18 |
Amgen Fremont Inc. |
Anticuerpos monoclonales humanos para quinasa-1 de tipo receptor de activina (ALK-1)
|
BRPI0616374B8
(pt)
*
|
2005-09-19 |
2021-05-25 |
Pah Usa 15 Llc |
forma i do sal de fosfato de um composto pirrol substituído 2-indolinona, composição farmacêutica, usos e método de preparação da forma i
|
CA2627598C
(en)
|
2005-11-07 |
2013-06-25 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
JP2009522276A
(ja)
*
|
2005-12-29 |
2009-06-11 |
ザ スクリップス リサーチ インスティテュート |
インドリノンベースのプロテインキナーゼ阻害剤のアミノ酸誘導体
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
CN101007801A
(zh)
*
|
2006-01-27 |
2007-08-01 |
上海恒瑞医药有限公司 |
吡咯取代的2-二氢吲哚酮衍生物、其制法与医药上的用途
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
KR20080110912A
(ko)
|
2006-04-19 |
2008-12-19 |
노파르티스 아게 |
인다졸 화합물 및 cdc7의 억제 방법
|
RS20080525A
(en)
|
2006-05-09 |
2009-09-08 |
Pfizer Products Inc., |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
CN101443009A
(zh)
*
|
2006-05-18 |
2009-05-27 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
DE102006024834B4
(de)
*
|
2006-05-24 |
2010-07-01 |
Schebo Biotech Ag |
Neue Indol-Pyrrol-Derivate und deren Verwendungen
|
US7838542B2
(en)
|
2006-06-29 |
2010-11-23 |
Kinex Pharmaceuticals, Llc |
Bicyclic compositions and methods for modulating a kinase cascade
|
EP2044939A1
(en)
*
|
2006-06-29 |
2009-04-08 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for liver fibrosis
|
EP2040738A1
(en)
|
2006-07-13 |
2009-04-01 |
Zymogenetics, Inc. |
Interleukin 21 and tyrosine kinase inhibitor combination therapy
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
TW200817409A
(en)
|
2006-08-04 |
2008-04-16 |
Takeda Pharmaceutical |
Fused heterocyclic derivative and use thereof
|
RS55881B1
(sr)
|
2006-08-23 |
2017-08-31 |
Kudos Pharm Ltd |
2-metilmorfolin pirido-,pirazo- i pirimido-pirimidin derivati kao inhibitori mtor-a
|
US8865737B2
(en)
|
2006-08-28 |
2014-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
EP2079727B1
(en)
|
2006-09-15 |
2016-02-17 |
Xcovery, INC. |
Kinase inhibitor compounds
|
WO2008057461A2
(en)
|
2006-11-02 |
2008-05-15 |
Acceleron Pharma, Inc. |
Alk1 receptor and ligand antagonists and uses thereof
|
WO2008056634A1
(fr)
*
|
2006-11-06 |
2008-05-15 |
Theravalues Corporation |
Nouveau dérivé d'hydroxyindole
|
JP5357763B2
(ja)
|
2006-11-06 |
2013-12-04 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
イミダゾ[1,2−b]ピリダジン誘導体およびピラゾロ[1,5−a]ピリダジン誘導体およびプロテインキナーゼインヒビターとしてのこれらの使用
|
JP5542445B2
(ja)
|
2006-12-04 |
2014-07-09 |
江▲蘇▼先声▲薬▼物研究有限公司 |
3−ピロロシクロへキシリデン−2−ジヒドロインドリノン誘導体およびその用途
|
EP2119707B1
(en)
|
2007-01-29 |
2015-01-14 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
MX2009008386A
(es)
|
2007-02-06 |
2009-10-16 |
Pfizer |
Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer.
|
EP2138497A4
(en)
|
2007-03-20 |
2012-01-04 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
US20090004213A1
(en)
|
2007-03-26 |
2009-01-01 |
Immatics Biotechnologies Gmbh |
Combination therapy using active immunotherapy
|
US20090042906A1
(en)
*
|
2007-04-26 |
2009-02-12 |
Massachusetts Institute Of Technology |
Methods for treating cancers associated with constitutive egfr signaling
|
WO2008138184A1
(fr)
|
2007-05-14 |
2008-11-20 |
Shanghai Hengrui Pharmaceutical Co.Ltd. |
Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
|
WO2008145398A1
(en)
*
|
2007-06-01 |
2008-12-04 |
Pfizer Italia S.R.L. |
4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors
|
CL2008001626A1
(es)
|
2007-06-05 |
2009-06-05 |
Takeda Pharmaceuticals Co |
Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
|
JP5270553B2
(ja)
|
2007-08-23 |
2013-08-21 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
US20090062368A1
(en)
*
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched sunitinib
|
HRP20161114T1
(hr)
*
|
2007-09-06 |
2016-11-04 |
Boston Biomedical, Inc. |
Sastavi inhibitora kinaze i njihova uporaba za liječenje raka i drugih bolesti povezanih s kinazama
|
CN101861321B
(zh)
|
2007-10-11 |
2013-02-06 |
阿斯利康(瑞典)有限公司 |
作为蛋白激酶b抑制剂的吡咯并[2,3-d]嘧啶衍生物
|
AU2008325608B2
(en)
|
2007-11-09 |
2013-03-14 |
Eisai R & D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
US20100256392A1
(en)
*
|
2007-11-21 |
2010-10-07 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of sunitinib base and processes for preparation thereof
|
CA2699305A1
(en)
*
|
2007-11-21 |
2009-05-28 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of sunitinib base and processes for preparation thereof
|
US8389562B2
(en)
*
|
2007-12-12 |
2013-03-05 |
Medichem, S.A. |
Polymorphic forms of a 3-pyrrole substituted 2-indolinone
|
HUE025192T2
(en)
|
2007-12-19 |
2016-01-28 |
Genentech Inc |
5-Anilinoimidazopyridines and application procedures
|
WO2009080694A1
(en)
|
2007-12-20 |
2009-07-02 |
Novartis Ag |
Thiazole derivatives used as pi 3 kinase inhibitors
|
BRPI0819505A2
(pt)
|
2007-12-21 |
2017-04-04 |
Genentech Inc |
"composto, composição farmacêutica, método para inibir o crescimento celular anormal e método para tratar uma doença inflamatória"
|
CN102036962B
(zh)
*
|
2008-01-29 |
2013-08-07 |
卫材R&D管理有限公司 |
血管生成抑制剂和紫杉烷的组合使用
|
EP2113248A1
(en)
|
2008-04-29 |
2009-11-04 |
Ratiopharm GmbH |
Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
|
EP2090306A1
(en)
|
2008-02-13 |
2009-08-19 |
Ratiopharm GmbH |
Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
US20100310668A1
(en)
*
|
2008-02-13 |
2010-12-09 |
Ratiopharm Gmbh |
Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
|
CN101255154B
(zh)
*
|
2008-02-18 |
2011-09-07 |
靳广毅 |
一种取代的2-吲哚啉酮衍生物和制备方法及其应用
|
WO2009104021A2
(en)
*
|
2008-02-21 |
2009-08-27 |
Generics [Uk] Limited |
Novel polymorphs and processes for their preparation
|
EP2098521A1
(en)
*
|
2008-03-06 |
2009-09-09 |
Ratiopharm GmbH |
Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
|
ES2391501T3
(es)
*
|
2008-03-31 |
2012-11-27 |
Teva Pharmaceutical Industries Ltd. |
Procedimientos para preparar sunitinib y sales del mismo
|
KR20100135910A
(ko)
*
|
2008-04-16 |
2010-12-27 |
낫코 파마 리미티드 |
수니티닙 염기의 신규한 다형 형태
|
US8158656B2
(en)
*
|
2008-05-16 |
2012-04-17 |
Shenzhen Chipscreen Biosciences Ltd. |
2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
EP2292613B1
(en)
*
|
2008-05-23 |
2015-09-30 |
Shanghai Institute of Pharmaceutical Industry |
Dihydroindolinone derivatives
|
US8263547B2
(en)
*
|
2008-05-28 |
2012-09-11 |
Massachusetts Institute Of Technology |
DISC-1 pathway activators in the control of neurogenesis
|
EP2313371B1
(en)
*
|
2008-06-13 |
2012-08-15 |
Medichem, S.A. |
Process for preparing a 3-pyrrole substituted 2-indolinone malate salt
|
CA2724310A1
(en)
*
|
2008-06-23 |
2009-12-30 |
Natco Pharma Limited |
Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
|
EP2138167A1
(en)
*
|
2008-06-24 |
2009-12-30 |
ratiopharm GmbH |
Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
WO2009156837A2
(en)
*
|
2008-06-26 |
2009-12-30 |
Medichem, S.A. |
Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
|
DE102008031038A1
(de)
|
2008-06-30 |
2009-12-31 |
Alexander Priv.-Doz. Dr. Dömling |
Sutent zur Anwendung in der Organtransplantation
|
BRPI0914942A2
(pt)
*
|
2008-06-30 |
2015-08-11 |
Cylene Pharmaceuticals Inc |
Compostos de oxindol
|
SG10201510586PA
(en)
|
2008-06-30 |
2016-01-28 |
Mesoblast Inc |
Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy
|
JP2011526615A
(ja)
*
|
2008-07-02 |
2011-10-13 |
ジェネリクス・(ユーケー)・リミテッド |
3−ピロール置換2−インドリノン誘導体の調製
|
CA2730079A1
(en)
*
|
2008-07-10 |
2010-01-14 |
Generics [Uk] Limited |
Processes for the preparation of crystalline forms of sunitinib malate
|
EP2342195B1
(en)
|
2008-07-24 |
2014-09-10 |
Medichem, S.A. |
Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
|
CA2731605A1
(en)
|
2008-07-24 |
2010-01-28 |
Teva Pharmaceutical Industries Ltd. |
Sunitinib and salts thereof and their polymorphs
|
US8993615B2
(en)
|
2008-08-08 |
2015-03-31 |
The Johns Hopkins University |
Compositions and methods for treatment of neurodegenerative disease
|
WO2010023473A2
(en)
*
|
2008-08-25 |
2010-03-04 |
Generics [Uk] Limited |
Novel crystalline form and processes for its preparation
|
EA023148B1
(ru)
|
2008-08-25 |
2016-04-29 |
Эмплиммьюн, Инк. |
Композиции на основе антагонистов pd-1 и их применение
|
JP2012500838A
(ja)
*
|
2008-08-25 |
2012-01-12 |
ジェネリクス・(ユーケー)・リミテッド |
スニチニブの新規な多形およびその調製方法
|
EA201170375A1
(ru)
*
|
2008-08-25 |
2012-03-30 |
Эмплиммьюн, Инк. |
Антагонисты pd-1 и способы их применения
|
KR20110066927A
(ko)
*
|
2008-09-05 |
2011-06-17 |
임페리얼 이노베이션스 리미티드 |
생체 내 영상화제로서 사용하기 위한 이사틴 유도체
|
AU2009294415B2
(en)
|
2008-09-19 |
2015-09-24 |
Medimmune Llc |
Antibodies directed to DLL4 and uses thereof
|
EP2350056A1
(en)
*
|
2008-10-10 |
2011-08-03 |
Medichem, S.A. |
Process for preparing a 3-pyrrole subsituted 2-indolinone malate salt
|
EP2181991A1
(en)
|
2008-10-28 |
2010-05-05 |
LEK Pharmaceuticals D.D. |
Novel salts of sunitinib
|
EP2186809A1
(en)
|
2008-11-13 |
2010-05-19 |
LEK Pharmaceuticals D.D. |
New crystal form of sunitinib malate
|
US20100222371A1
(en)
*
|
2008-11-20 |
2010-09-02 |
Children's Medical Center Corporation |
Prevention of surgical adhesions
|
JP5579619B2
(ja)
|
2008-12-01 |
2014-08-27 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
JO3101B1
(ar)
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
US20110053923A1
(en)
|
2008-12-22 |
2011-03-03 |
Astrazeneca |
Chemical compounds 610
|
EP2379595A2
(en)
|
2008-12-23 |
2011-10-26 |
AstraZeneca AB |
Targeted binding agents directed to 5 1 and uses thereof
|
US8329740B2
(en)
|
2009-01-02 |
2012-12-11 |
Hetero Research Foundation |
Polymorphs of sunitinib malate
|
TWI577664B
(zh)
|
2009-01-16 |
2017-04-11 |
艾克塞里克斯公司 |
N-(4-{〔6,7-雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺蘋果酸鹽、包含其之醫藥組合物及其用途
|
AU2010210646B2
(en)
|
2009-02-05 |
2015-10-29 |
Immunogen, Inc. |
Novel benzodiazepine derivatives
|
AU2010210986A1
(en)
|
2009-02-09 |
2011-08-25 |
Supergen, Inc. |
Pyrrolopyrimidinyl Axl kinase inhibitors
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
WO2010098888A1
(en)
*
|
2009-02-27 |
2010-09-02 |
Massachusetts Institute Of Technology |
Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
|
US8785457B2
(en)
|
2009-03-13 |
2014-07-22 |
Cellzome Limited |
Pyrimidine derivatives as mTOR inhibitors
|
WO2010108503A1
(en)
|
2009-03-24 |
2010-09-30 |
Life & Brain Gmbh |
Promotion of neuronal integration in neural stem cell grafts
|
CA2758614A1
(en)
|
2009-04-14 |
2010-10-21 |
Cellzome Limited |
Fluoro substituted pyrimidine compounds as jak3 inhibitors
|
US8530492B2
(en)
|
2009-04-17 |
2013-09-10 |
Nektar Therapeutics |
Oligomer-protein tyrosine kinase inhibitor conjugates
|
EP2255792A1
(en)
|
2009-05-20 |
2010-12-01 |
Ratiopharm GmbH |
Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
|
US8211901B2
(en)
|
2009-05-22 |
2012-07-03 |
Shenzhen Chipscreen Biosciences Ltd. |
Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
|
EP2264027A1
(en)
*
|
2009-05-27 |
2010-12-22 |
Ratiopharm GmbH |
Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
CN101906076B
(zh)
|
2009-06-04 |
2013-03-13 |
深圳微芯生物科技有限责任公司 |
作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
WO2011004200A1
(en)
|
2009-07-10 |
2011-01-13 |
Generics [Uk] Limited |
Novel pyrrole derivatives
|
FR2948940B1
(fr)
*
|
2009-08-04 |
2011-07-22 |
Servier Lab |
Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
CA2771675A1
(en)
|
2009-09-11 |
2011-03-17 |
Cellzome Limited |
Ortho substituted pyrimidine compounds as jak inhibitors
|
AU2010296849A1
(en)
|
2009-09-16 |
2012-05-03 |
Ranbaxy Laboratories Limited |
Salts of sunitinib
|
US9242987B2
(en)
|
2009-10-20 |
2016-01-26 |
Cellzome Limited |
Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
|
WO2011058521A2
(en)
|
2009-11-12 |
2011-05-19 |
Ranbaxy Laboratories Limited |
Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
|
WO2011061613A1
(en)
|
2009-11-19 |
2011-05-26 |
Ranbaxy Laboratories Limited |
Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib
|
SMT202000195T1
(it)
|
2009-11-24 |
2020-05-08 |
Medimmune Ltd |
Agenti leganti direzionati contro b7-h1
|
EP2507237A1
(en)
|
2009-12-03 |
2012-10-10 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imidazoquinolines which act via toll - like receptors (tlr)
|
US10166142B2
(en)
|
2010-01-29 |
2019-01-01 |
Forsight Vision4, Inc. |
Small molecule delivery with implantable therapeutic device
|
WO2011095802A1
(en)
|
2010-02-02 |
2011-08-11 |
Generics [Uk] Limited |
Hplc method for analyzing sunitinib
|
WO2011100325A2
(en)
|
2010-02-09 |
2011-08-18 |
Sicor Inc. |
Polymorphs of sunitinib salts
|
BR112012020102A2
(pt)
|
2010-02-10 |
2016-11-29 |
Immunogen Inc |
anticorpos cd20 e usos dos mesmos.
|
WO2011101429A1
(en)
|
2010-02-22 |
2011-08-25 |
F. Hoffmann-La Roche Ag |
Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
|
WO2011104555A2
(en)
|
2010-02-25 |
2011-09-01 |
Generics [Uk] Limited |
Novel process
|
US9249129B2
(en)
|
2010-03-04 |
2016-02-02 |
Cellzome Limited |
Morpholino substituted urea derivatives as mTOR inhibitors
|
CA2792039A1
(en)
|
2010-03-04 |
2011-09-09 |
Ranbaxy Laboratories Limited |
Process for the direct preparation of malic acid salt of sunitinib
|
EP2545034A1
(en)
|
2010-03-10 |
2013-01-16 |
Synthon B.V. |
A process for amidation of pyrrole carboxylate compounds
|
CA2793359A1
(en)
|
2010-03-18 |
2011-09-22 |
Ranbaxy Laboratories Limited |
Process for the preparation of malic acid salt of sunitinib
|
WO2011119777A2
(en)
|
2010-03-23 |
2011-09-29 |
The Johns Hopkins University |
Compositions and methods for treatment of neurodegenerative disease
|
WO2011128699A2
(en)
|
2010-04-16 |
2011-10-20 |
Generics [Uk] Limited |
Novel process
|
JP2013525392A
(ja)
|
2010-04-30 |
2013-06-20 |
セルゾーム リミティッド |
Jak阻害剤としてのピラゾール化合物
|
WO2011138565A1
(fr)
|
2010-05-05 |
2011-11-10 |
Biorebus |
Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
|
EP2392324A1
(en)
|
2010-06-01 |
2011-12-07 |
Societe De Coordination De Recherches Therapeutiques |
Rhenium complexes and their pharmaceutical use
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
CN102958523B
(zh)
|
2010-06-25 |
2014-11-19 |
卫材R&D管理有限公司 |
使用具有激酶抑制作用的组合的抗肿瘤剂
|
EP2588105A1
(en)
|
2010-07-01 |
2013-05-08 |
Cellzome Limited |
Triazolopyridines as tyk2 inhibitors
|
EP2591004A1
(en)
|
2010-07-09 |
2013-05-15 |
F.Hoffmann-La Roche Ag |
Anti-neuropilin antibodies and methods of use
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
WO2012022681A2
(en)
|
2010-08-20 |
2012-02-23 |
Cellzome Limited |
Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
|
US8426418B2
(en)
|
2010-08-27 |
2013-04-23 |
CollabRx Inc. |
Method to treat melanoma in BRAF inhibitor-resistant subjects
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
BR112013010920A2
(pt)
|
2010-11-01 |
2016-07-12 |
Scinopharm Kunshan Biochemical Technology Co Ltd |
processos para a preparação de 3 - ((pirrol-2-il)metileno)-2-pirrolonas utilizando 2-sillixa-pirrolas
|
WO2012059941A1
(en)
*
|
2010-11-04 |
2012-05-10 |
Ind-Swift Laboratories Limited |
Process for preparation of sunitinib malate and salts thereof
|
WO2012062704A1
(en)
|
2010-11-09 |
2012-05-18 |
Cellzome Limited |
Pyridine compounds and aza analogues thereof as tyk2 inhibitors
|
WO2012068487A1
(en)
|
2010-11-18 |
2012-05-24 |
Synta Pharmaceuticals Corp. |
Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
|
CA2818612C
(en)
|
2010-11-19 |
2020-12-29 |
Forsight Vision4, Inc. |
Therapeutic agent formulations for implanted devices
|
AR083868A1
(es)
|
2010-12-03 |
2013-03-27 |
Lilly Co Eli |
Compuestos de oxazol[5,4-b]piridin-5-ilo
|
WO2012088529A1
(en)
|
2010-12-23 |
2012-06-28 |
Nektar Therapeutics |
Polymer-sunitinib conjugates
|
EP2654797B1
(en)
|
2010-12-23 |
2017-11-08 |
Nektar Therapeutics |
Polymer-des-ethyl sunitinib conjugates
|
UY33883A
(es)
|
2011-01-31 |
2012-08-31 |
Novartis Ag |
Novedosos derivados heterocíclicos
|
BR112013020540B1
(pt)
|
2011-02-15 |
2020-12-29 |
Immunogen, Inc |
métodos para preparação de conjugados compreendendo agente de ligação à célula conjugado a composto citotóxico com grupo ligante
|
ES2691673T3
(es)
|
2011-02-17 |
2018-11-28 |
Cancer Therapeutics Crc Pty Limited |
Inhibidores de Fak
|
DK2675794T3
(da)
|
2011-02-17 |
2019-05-06 |
Cancer Therapeutics Crc Pty Ltd |
Selektive fak-inhibitorer
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
US8630703B2
(en)
|
2011-03-09 |
2014-01-14 |
Technion Research & Development Foundation Limited |
Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination
|
CN102115469A
(zh)
*
|
2011-03-21 |
2011-07-06 |
浙江大学 |
吲哚啉-2-酮类衍生物的制备和用途
|
EP2694511A1
(en)
|
2011-04-04 |
2014-02-12 |
Cellzome Limited |
Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
|
WO2012139019A2
(en)
|
2011-04-08 |
2012-10-11 |
Beta Pharma, Inc. |
New indolinone protein kinase inhibitors
|
MX2013009931A
(es)
|
2011-04-18 |
2013-10-01 |
Eisai R&D Man Co Ltd |
Agentes terapeuticos contra tumores.
|
WO2012143320A1
(en)
|
2011-04-18 |
2012-10-26 |
Cellzome Limited |
(7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
|
CN102898402B
(zh)
*
|
2011-04-26 |
2016-01-20 |
北京大学 |
一种苯并异硒唑酮修饰的吡咯甲酸酯取代的吲哚酮类化合物及其应用
|
ES2841809T3
(es)
|
2011-06-03 |
2021-07-09 |
Eisai R&D Man Co Ltd |
Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
|
EP3409278B8
(en)
|
2011-07-21 |
2020-11-04 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Heterocyclic protein kinase inhibitors
|
WO2013014162A1
(en)
|
2011-07-28 |
2013-01-31 |
Cellzome Limited |
Heterocyclyl pyrimidine analogues as jak inhibitors
|
WO2013017479A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
WO2013017480A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
US20140323504A1
(en)
|
2011-09-20 |
2014-10-30 |
Cellzome Limited |
Pyrazolo[4,3-c]Pyridine Derivatives As Kinase Inhibitors
|
JP5995975B2
(ja)
|
2011-09-21 |
2016-09-21 |
セルゾーム リミテッド |
Mtor阻害剤としてのモルホリノ置換尿素またはカルバメート誘導体
|
ES2592219T3
(es)
|
2011-10-07 |
2016-11-28 |
Cellzome Limited |
Derivados de {(4-(4-morfolino-dihidrotieno[3,4-d]pirimidin-2-il)aril}urea o carbamato como inhibidores de mTOR
|
CN102499917B
(zh)
|
2011-10-25 |
2014-12-17 |
澳门大学 |
吲哚酮类化合物在制备神经保护药物中的应用
|
ES2587533T3
(es)
|
2011-10-28 |
2016-10-25 |
Novartis Ag |
Derivados de purina y su uso en el tratamiento de enfermedades
|
CN103130774B
(zh)
*
|
2011-11-22 |
2016-06-22 |
齐鲁制药有限公司 |
具有酪氨酸激酶抑制作用的化合物及其制备方法和应用
|
CN103127096B
(zh)
*
|
2011-12-02 |
2015-11-25 |
杨子娇 |
吡咯基取代的吲哚类化合物在治疗青光眼病的应用
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
RU2014130214A
(ru)
|
2011-12-23 |
2016-02-10 |
Целльзом Лимитид |
Пиримидин-2, 4-диаминовые производные в качестве ингибиторов киназы
|
CN102491932A
(zh)
*
|
2011-12-26 |
2012-06-13 |
天津科技大学 |
一种3-吲哚啉酮类衍生物及其制备方法及其应用
|
CN104114550A
(zh)
|
2012-03-23 |
2014-10-22 |
劳拉斯实验室私人有限公司 |
制备舒尼替尼及其酸加成盐的改进的方法
|
IN2014MN02105A
(forum.php)
|
2012-04-20 |
2015-09-11 |
Annji Pharm Co Ltd |
|
CN102653521B
(zh)
*
|
2012-04-27 |
2014-08-06 |
首都师范大学 |
吲哚-2-酮的哌嗪硫代甲酰肼衍生物及其制备方法和用途
|
PL399027A1
(pl)
|
2012-04-27 |
2013-10-28 |
Instytut Farmaceutyczny |
Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
|
KR101728483B1
(ko)
|
2012-05-04 |
2017-04-19 |
화이자 인코포레이티드 |
전립선 관련된 항원 및 백신 기재 면역치료 요법
|
EP2849756A1
(en)
|
2012-05-16 |
2015-03-25 |
Novartis AG |
Dosage regimen for a pi-3 kinase inhibitor
|
HUE043552T2
(hu)
|
2012-06-08 |
2019-09-30 |
Sutro Biopharma Inc |
Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
|
US9732161B2
(en)
|
2012-06-26 |
2017-08-15 |
Sutro Biopharma, Inc. |
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
AU2013302320A1
(en)
|
2012-08-17 |
2015-02-26 |
Cancer Therapeutics Crc Pty Limited |
VEGFR3 inhibitors
|
WO2014031566A1
(en)
|
2012-08-22 |
2014-02-27 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
SG11201501464TA
(en)
|
2012-08-31 |
2015-03-30 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
WO2014045101A1
(en)
|
2012-09-21 |
2014-03-27 |
Cellzome Gmbh |
Tetrazolo quinoxaline derivatives as tankyrase inhibitors
|
JP6243918B2
(ja)
|
2012-10-16 |
2017-12-06 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
Pkm2調節因子およびそれらの使用方法
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
JPWO2014098176A1
(ja)
|
2012-12-21 |
2017-01-12 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キノリン誘導体のアモルファス及びその製造方法
|
EP2961435B1
(en)
|
2013-02-28 |
2019-05-01 |
ImmunoGen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
JP6494533B2
(ja)
|
2013-02-28 |
2019-04-03 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
|
CN105408320B
(zh)
*
|
2013-03-13 |
2019-08-13 |
北京强新生物科技有限公司 |
用于治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物
|
EP2968113B8
(en)
|
2013-03-14 |
2020-10-28 |
Forsight Vision4, Inc. |
Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
|
WO2014151871A2
(en)
|
2013-03-14 |
2014-09-25 |
Tolero Pharmaceuticals, Inc. |
Jak2 and alk2 inhibitors and methods for their use
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
CN104119321B
(zh)
*
|
2013-04-28 |
2017-09-08 |
齐鲁制药有限公司 |
二氢吲哚酮衍生物的二马来酸盐及其多晶型物
|
NZ714049A
(en)
|
2013-05-14 |
2020-05-29 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
EP3019522B1
(en)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
FR3008411B1
(fr)
*
|
2013-07-12 |
2015-07-03 |
Servier Lab |
Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
|
CN105659085B
(zh)
|
2013-08-28 |
2018-12-07 |
中美冠科生物技术(太仓)有限公司 |
预测受试者对多激酶抑制剂的反应的基因表达标志及其使用方法
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
US9278955B2
(en)
|
2013-10-18 |
2016-03-08 |
Sun Pharmaceutical Industries Limited |
Ascorbic acid salt of sunitinib
|
US9604968B2
(en)
|
2013-10-18 |
2017-03-28 |
Sun Pharmaceutical Industries Limited |
Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
|
EP3524262A1
(en)
|
2013-11-01 |
2019-08-14 |
Pfizer Inc |
Vectors for expression of prostate-associated antigens
|
HUE057092T2
(hu)
|
2013-12-06 |
2022-04-28 |
Novartis Ag |
Alfa-izoformára szelektív foszfatidilinozitol-3-kináz-inhibitor adagolási rendje
|
CN104829596B
(zh)
*
|
2014-02-10 |
2017-02-01 |
石家庄以岭药业股份有限公司 |
吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
|
CN103923014A
(zh)
*
|
2014-05-05 |
2014-07-16 |
宁夏宝马药业有限公司 |
环肌酸制备方法
|
SG11201700943TA
(en)
|
2014-08-08 |
2017-03-30 |
Forsight Vision4 Inc |
Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
|
RS63559B1
(sr)
|
2014-08-28 |
2022-10-31 |
Eisai R&D Man Co Ltd |
Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
EP4599890A2
(en)
|
2015-01-13 |
2025-08-13 |
Kyoto University |
Sunitinib for preventing and/or treating amyotrophic lateral sclerosis
|
SG11201706630UA
(en)
|
2015-02-25 |
2017-09-28 |
Eisai R&D Man Co Ltd |
Method for suppressing bitterness of quinoline derivative
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
JP6851978B2
(ja)
|
2015-04-20 |
2021-03-31 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ミトコンドリアプロファイリングによるアルボシジブ応答の予測
|
WO2016184793A1
(en)
|
2015-05-15 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
|
CN111349118B
(zh)
|
2015-05-18 |
2023-08-22 |
住友制药肿瘤公司 |
具有增加的生物利用度的阿伏西地前药
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
SG11201710198YA
(en)
|
2015-06-16 |
2018-01-30 |
Eisai R&D Man Co Ltd |
Anticancer agent
|
AU2016301315C1
(en)
|
2015-08-03 |
2022-07-07 |
Sumitomo Pharma Oncology, Inc. |
Combination therapies for treatment of cancer
|
ES2887426T3
(es)
|
2015-08-20 |
2021-12-22 |
Eisai R&D Man Co Ltd |
Lenvatinib combinado con etopósido e ifosfamida para su uso en el tratamiento de un tumor
|
BR112018005589A2
(pt)
|
2015-09-22 |
2018-10-09 |
Graybug Vision Inc |
“composto, composição farmaceuticamente aceitável, e, uso de um composto”
|
GB2543550A
(en)
|
2015-10-21 |
2017-04-26 |
Hox Therapeutics Ltd |
Peptides
|
US20180280370A1
(en)
|
2015-11-02 |
2018-10-04 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
BR112018009644A2
(pt)
|
2015-11-12 |
2018-11-06 |
Graybug Vision Inc |
micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
|
JP7306827B2
(ja)
|
2016-01-27 |
2023-07-11 |
ストロ バイオファーマ インコーポレーテッド |
抗cd74抗体コンジュゲート、抗cd74抗体コンジュゲートを含む組成物および抗cd74抗体コンジュゲートを使用する方法
|
JP2019508405A
(ja)
|
2016-02-08 |
2019-03-28 |
ヴィトリサ セラピューティクス, インコーポレイテッド |
改良された硝子体内半減期を有する組成物およびその使用
|
EP3228630A1
(en)
|
2016-04-07 |
2017-10-11 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
|
CN107459519A
(zh)
|
2016-06-06 |
2017-12-12 |
上海艾力斯医药科技有限公司 |
稠合嘧啶哌啶环衍生物及其制备方法和应用
|
CA3035081A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
AU2017348322B8
(en)
|
2016-10-28 |
2021-12-23 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating EZH2-mediated cancer
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
US10287253B2
(en)
|
2016-12-05 |
2019-05-14 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
US11541051B2
(en)
|
2016-12-08 |
2023-01-03 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating CDK4/6-mediated cancer
|
US10132797B2
(en)
|
2016-12-19 |
2018-11-20 |
Tolero Pharmaceuticals, Inc. |
Profiling peptides and methods for sensitivity profiling
|
CA3044658A1
(en)
|
2017-02-08 |
2018-08-16 |
Eisai R&D Management Co., Ltd. |
Tumor-treating pharmaceutical composition
|
CN106916143B
(zh)
*
|
2017-03-14 |
2019-09-27 |
哈尔滨医科大学 |
一种预防和治疗冠心病的药物及其应用
|
WO2018175922A1
(en)
|
2017-03-23 |
2018-09-27 |
Graybug Vision, Inc. |
Drugs and compositions for the treatment of ocular disorders
|
CN111201040A
(zh)
|
2017-05-10 |
2020-05-26 |
灰色视觉公司 |
用于医学疗法的缓释微粒及其悬浮液
|
RU2019134940A
(ru)
|
2017-05-16 |
2021-06-16 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Лечение гепатоцеллюлярной карциномы
|
EP3658588A1
(en)
|
2017-07-26 |
2020-06-03 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
SG11202002310UA
(en)
|
2017-09-18 |
2020-04-29 |
Sutro Biopharma Inc |
Anti- folate receptor alpha antibody conjugates and their uses
|
WO2019075367A1
(en)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
AU2019231689A1
(en)
|
2018-03-06 |
2020-09-24 |
Icahn School Of Medicine At Mount Sinai |
Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
|
EP3539536A1
(en)
|
2018-03-15 |
2019-09-18 |
MH10 Spolka z ograniczona odpowiedzialnoscia |
A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
|
WO2020216450A1
(en)
|
2019-04-25 |
2020-10-29 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous sunitinib
|
JP7351859B2
(ja)
|
2018-06-04 |
2023-09-27 |
アプロス セラピューティクス, インコーポレイテッド |
Tlr7の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
AU2019288740A1
(en)
|
2018-06-21 |
2021-01-14 |
Icahn School Of Medicine At Mount Sinai |
WD40 repeat domain protein 5 (WDR5) degradation / disruption compounds and methods of use
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
KR20210038906A
(ko)
|
2018-07-26 |
2021-04-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
|
WO2020060944A1
(en)
|
2018-09-17 |
2020-03-26 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
MX2021006544A
(es)
|
2018-12-04 |
2021-07-07 |
Sumitomo Pharma Oncology Inc |
Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
|
KR20210107069A
(ko)
|
2018-12-21 |
2021-08-31 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 컨쥬게이트와 키나아제 저해제의 조합
|
WO2020167990A1
(en)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
BR112021018168B1
(pt)
|
2019-03-21 |
2023-11-28 |
Onxeo |
Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
|
US11712433B2
(en)
|
2019-03-22 |
2023-08-01 |
Sumitomo Pharma Oncology, Inc. |
Compositions comprising PKM2 modulators and methods of treatment using the same
|
WO2020227105A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
CA3137916A1
(en)
|
2019-05-06 |
2020-11-12 |
Ichan School Of Medicine At Mount Sinai |
Heterobifunctional compounds as degraders of hpk1
|
EP4023639A1
(en)
|
2019-08-31 |
2022-07-06 |
Etern Biopharma (Shanghai) Co., Ltd. |
Pyrazole derivative for fgfr inhibitor and preparation method therefor
|
CA3159348A1
(en)
|
2019-11-08 |
2021-05-14 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
EP4114852A1
(en)
|
2020-03-03 |
2023-01-11 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
CN111233841A
(zh)
*
|
2020-03-17 |
2020-06-05 |
湖北扬信医药科技有限公司 |
一种舒尼替尼有关物质及其制备方法和用途
|
US12103924B2
(en)
|
2020-06-01 |
2024-10-01 |
Icahn School Of Medicine At Mount Sinai |
Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
|
JP7633786B2
(ja)
|
2020-09-18 |
2025-02-20 |
日本化薬株式会社 |
スニチニブリンゴ酸塩を有効成分とする医薬錠剤
|
US20240293365A1
(en)
*
|
2021-06-28 |
2024-09-05 |
The Regents Of The University Of California |
Methods for treating and ameliorating t cell related diseases
|
CN113717159A
(zh)
*
|
2021-09-16 |
2021-11-30 |
中国药科大学 |
吲哚酮类化合物及其药物组合物、制备方法及用途
|
WO2023081923A1
(en)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
JP2025517908A
(ja)
|
2022-05-24 |
2025-06-12 |
第一三共株式会社 |
抗cdh6抗体-薬物コンジュゲートの投薬量レジメン
|
IL317782A
(en)
|
2022-06-30 |
2025-02-01 |
Sutro Biopharma Inc |
Anti-ROR1 antibodies and conjugates thereof, compositions containing anti-ROR1 antibodies or conjugates thereof, and methods for preparing and using anti-ROR1 antibodies and conjugates thereof
|
WO2024017372A1
(zh)
*
|
2022-07-22 |
2024-01-25 |
成都百裕制药股份有限公司 |
一种吲哚酮衍生物及其应用
|
CN118221652B
(zh)
*
|
2022-12-19 |
2025-06-06 |
沈阳药科大学 |
一种吲哚-2-酮衍生物及其制备方法和用途
|
WO2024188282A1
(zh)
*
|
2023-03-14 |
2024-09-19 |
康百达(四川)生物医药科技有限公司 |
吲哚酮衍生物及其在医药上的应用
|
WO2025081117A2
(en)
|
2023-10-13 |
2025-04-17 |
Sutro Biopharma, Inc. |
Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
|